SCM
ALLO icon

Sio Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Sio Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Buy
+13,323,431
New +$29.3M 4.59% 4

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sio Capital Management's ALLO Position: Q2 2026 in Review

Sio Capital Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 13,323,431 shares worth $27.7M. The stake represents 4.59% of the portfolio and ranks #4 among its holdings.

195 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Sio Capital Management held 13,323,431 shares of Allogene Therapeutics worth $27.7M as of Q2 2026.
  • Allogene Therapeutics was a new Sio Capital Management position in Q2 2026.
  • Allogene Therapeutics made up 4.59% of Sio Capital Management's portfolio in Q2 2026, its #4 holding.
  • 195 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.